Navigation Links
3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM)
Date:1/8/2010

SHENYANG, China, Jan. 8 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use. Feraheme is an intravenous iron therapy that 3SBio licensed from AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) for development in China for the treatment of iron deficiency anemia in adult patients with chronic kidney disease ("CKD").

Feraheme was approved on June 30, 2009 by the U.S. Food and Drug Administration for the same indication for which 3SBio is seeking approval in China and launched commercially in the U.S. by AMAG in July 2009. As previously announced, 3SBio has exclusive rights to develop and commercialize Feraheme in China. Once approved by the SFDA, 3SBio will commence a multi-center randomized efficacy and safety study in China with approximately 200 CKD patients, measuring the mean change in hemoglobin from baseline at Day 35 after first dose.

Dr. Jing Lou, Chief Executive Officer of 3SBio comments: "We are pleased with the timely submission of the Feraheme clinical trial application to the SFDA in China, representing a major milestone and our commitment to bringing this innovative therapy to Chinese CKD patients in need. We look forward to working with the SFDA to ensure an efficient review process."

Brian J.G. Pereira, MD, President and Chief Executive Officer of AMAG Pharmaceuticals comments: "3SBio is the ideal partner to bring Fer
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 3SBio Inc. Announces Unaudited Third Quarter 2009 Results
2. 3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009
3. 3SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009
4. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
5. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
6. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
7. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
8. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
9. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. Files for SFDA Approval of NuLeusin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... , today announced that it will release its unaudited financial ... market close on Thursday, August 14, 2014 EDT. The Company ... on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, ... review the Company,s financial results and provide an update on ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... China Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China ... health and nutritional food industry,engaged in the development, ... and raw cactus plants in the People,s,Republic of ... Mr. Ren,Hu will present at the upcoming Roth ...
... Uroplasty, Inc. (Amex:,UPI) announced today that it will ... on Monday, November 10, 2008 at the New York,Palace ... Chief Executive,Officer and Medi Jiwani, Vice President and Chief ... financial,performance at 4:55 p.m. Eastern Time., Attendance at ...
... in medicine. Although no significant achievements for curing disease have been achieved, ... approaches. By the year 2015, global market for gene therapy is projected ... ... 2008 -- Advancements in gene therapy have provided useful data, which has ...
Cached Biology Technology:China Yingxia to Present at Roth China Comes to Vegas Conference 2Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... the AIDS virus,s protein envelope once considered an improbable target ... most promising, new research by Dana-Farber Cancer Institute scientists indicates. ... the V3 loop, is an attractive vaccine target because immune ... multiple genetic subtypes of HIV-1, the virus that causes AIDS. ...
... "skin" of most every cell in your body, but the ... be rendered by many experimental techniques. A team of scientists ... and University of California, Irvine, recently developed a way to ... role of cholesterol within this boundary between the cell and ...
... Minnesota finalized a license agreement for CaSTT (Commerce and ... for technology transfer offices in universities and research institutions. ... consulting services that allow technology transfer offices to make ... and, in some cases, execute licenses from start to ...
Cached Biology News:Study identifies promising target for AIDS vaccine 2Study identifies promising target for AIDS vaccine 3Closer look at cell membrane shows cholesterol 'keeping order' 2